Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orly Lipsitz

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 8, 2020
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatmentAshley N Siegel, Nelson Rodrigues, Flora Nasri, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|July 8, 2020
Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatmentAshley N Siegel, Nelson Rodrigues, Flora Nasri, et al.
Psychopharmacology|January 23, 2021
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatmentJason Ng, Leanna M W Lui, Joshua D Rosenblat, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|October 8, 2020
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceOrly Lipsitz, Roger S McIntyre, Nelson B Rodrigues, et al.
CNS Drugs|August 7, 2021
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood DisordersFelicia Ceban, Joshua D Rosenblat, Kevin Kratiuk, et al.
Psychiatry Research|November 19, 2021
Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effectsTuyen T Le, Joshua D Di Vincenzo, Kayla M Teopiz, et al.
Journal of Affective Disorders|July 16, 2020
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of ExcellenceRoger S McIntyre, Nelson B Rodrigues, Yena Lee, et al.
Journal of Affective Disorders|September 3, 2020
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysisRoger S McIntyre, Isabelle P Carvalho, Leanna M W Lui, et al.
Pageof 6